15th Jul 2019 12:55
(Alliance News) - Oncimmune Holdings PLC on Monday said Sabartech SL, its existing distributor in Spain and Portugal, has agreed with Vithas Group to sell EarlyCDT Lung as a screening test for early detection of lung cancer.
Vithas is the Spanish private healthcare company, which will also promote the test across Spain to further increase awareness of EarlyCDT Lung.
The AIM-listed immunodiagnostics company said Vithas operates 48 hospitals and medical centres across Spain and has been growing strongly through the opening of new facilities.
Oncimmune said this commercial agreement increases the reach of EarlyCDT Lung in large European and North American healthcare markets and validates the product's increasing acceptance within major healthcare systems.
"Today's announcement further demonstrates the success of our partnership with Sabartech for the distribution of EarlyCDT Lung across the Iberian Peninsula," said Chief Executive Adam Hill.
He added: "The news highlights the growing momentum behind our business and further validates our strategy of creating value through partnering to unlock the potential of the EarlyCDT portfolio."
Oncimmune shares were trading 4.8% lower on Monday in London at 95.20 pence each.
Related Shares:
Oncimmune